Analysts expect that Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) will post $1.79 million in sales for the current fiscal quarter, Zacks Investment Research reports. Three analysts have provided estimates for Dicerna Pharmaceuticals’ earnings, with the lowest sales estimate coming in at $1.70
Pipeline giant Kinder Morgan (NYSE:KMI) has been on the upswing in recent days after reporting better than expected Q3 2016 results. The company was able to hit most of the marks analysts were looking for, lowering debt and leverage as well as providing a crucial update to its capital return (dividends) plans.
Both in the U.S. and internationally, marijuana — especially the medical variety — is getting more and more accepted with time. So, how do you invest in it? In this episode of MarketFoolery, host Chris Hill talks with Motley Fool analyst Shannon Jones about how to get exposure to the fledgling industry without buying into the ever-risky penny stocks that make up most of the U.S. marijuana....More>>>
Vancouver-based mineral exploration and development company Kootenay Zinc Corp. (OTCQB:KTNNF)(CSE:ZNK.CN)(CSE:ZNK)(FRANKFURT:KYH) is currently in the process of developing a massive new greenfield mining megaproject that if successful would trigger a significant adjustment in the configuration of North American zinc production. Dubbed Sully in homage to the nearby Sullivan Deposititself an....More>>>
Media stories about Kyocera (NYSE:KYO) have trended somewhat positive this week, according to Accern. The research firm ranks the sentiment of press coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one